Is this you?
Request access for SCRI with your @scri.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
SCRI
Unclaimed profileSite Network · Multiple locations across US (200+ locations in 20+ states) · ~200 sites
Intera lens
ICP 9Lift (cardio sample) 0.05Recruit soph 0.57
Quality Scorecard (1–100)
Overall72Recruit49Ops73Sponsor90Ther83
Performance (observed)
Historical trials
518
Completed
153
Terminated/Withdrawn
74
Completion rate
67%
Active now
287
Phase 2
196
Phase 3
144
Realized enrollment
90,436
First study year
2006
Years active
20
Match confidence
low
Enrollment velocity (inf)
4,522
Therapeutic
Areas
Oncology, Cancer, Medical Oncology
Specialties
Oncology focus; 900+ first-in-human trials; GI, lung, breast, GYN, CNS, GU, hematologic cancers
Breadth (conditions)
682
Languages
English + Spanish (detected)
States
Colorado, Tennessee, Texas, and 17+ additional states
Recruitment (web observed)
Trial Finder
Yes
Patient database
Y
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Strong (extensive content on oncology trials)
Capability notes
National leader in oncology, 1,500+ physicians, 200+ locations, significant enrollment capacity
Relationships
Sponsors
Hoffmann-La Roche; Eli Lilly and Company; Genentech, Inc.; Pfizer; Merck Sharp & Dohme LLC; Bristol-Myers Squibb
CROs
ICON Clinical Research; IQVIA Pty Ltd; PPD Development, LP
Partnerships
2022 joint venture with former US Oncology Research; Accelero platform
Owner / parent
Sarah Cannon Research Institute (formed 2022 joint venture with former US Oncology Research)
Acquisitions
Joint venture with US Oncology Research (2022)
Expansion
Y (2022 expansion via US Oncology joint venture)
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown (executive/scientific leadership team mentioned)
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
Clemence.Walker@scri.com
Tech & DCT
eSource
Yes
Builds tech
Vendors
Home visits
N
DCT / decentralized
N (community oncology settings only)
Tech stack
Advanced oncology research platforms, centralized data management
Recruiting visible
Y
Notes
CTGOV Signal: 5 recruiting trials across 3 locations (Colorado, Tennessee, Texas). Global leader in oncology research, 30+ years experience. Conducted 900+ first-in-human trials. Contributed to majority of new FDA-approved cancer therapies in past decade. 1,500 research physicians across 200+ US locations in 20+ states. Large-scale, enterprise-level operation.
Recommendation features (sample indication)
Ind fit 0.12Liftability 0.05Overall72
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.